PAUF-Binding Antibody Engineering for Selective Cancer Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs, including chemotherapeutic and biotherapeutic agents, face limitations in specificity and toxicity, necessitating the development of antibodies with higher affinity and specificity for pancreatic adenocarcinoma upregulated factor (PAUF) proteins to enhance cancer diagnosis and treatment efficacy.
Innovation Solution
Development of chimeric and humanized antibodies with specific CDR sequences that bind to PAUF proteins, inhibiting proliferation, migration, and invasion of cancer cells, including pancreatic and ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat cancer, then cancer cells are killed, but normal cells are also damaged and tolerance develops
Solution Approach 1:
The patent segments the treatment approach by using monoclonal antibodies that specifically target cancer cells through their unique surface antigens, separating the effect on cancer cells from normal cells. The antibody-drug conjugate further segments the delivery system, attaching cytotoxic drugs to antibodies that only bind to cancer cell surfaces, ensuring localized delivery.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediaries between the therapeutic agent and cancer cells. These antibodies specifically recognize and bind to cancer cell surface antigens, mediating the delivery of therapeutic effects while sparing normal cells. The antibody acts as a selective mediator that bridges the gap between systemic administration and targeted cancer cell destruction.
2Reliability
If existing anti-PAUF human antibodies are used, then cancer treatment is provided, but binding affinity and specificity need improvement
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through CDR region optimization and humanization. The complementarity-determining regions are engineered to enhance binding affinity parameters, while maintaining human compatibility. The antibody sequence is optimized to improve kinetic parameters such as association and dissociation rates, achieving superior binding characteristics.
3Object-affected harmful factors
If monoclonal antibodies with high specificity are developed, then side effects are reduced, but development complexity increases
Solution Approach 1:
The patent uses copying by generating multiple monoclonal antibodies through hybridoma technology, creating a library of antibodies with different specificities. This allows selection of the most effective antibody while distributing development risk across multiple candidates. The antibody-drug conjugate approach also copies the successful targeting mechanism of antibodies while adding therapeutic functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies exhibit higher affinity and specificity for PAUF proteins, effectively inhibiting cancer cell proliferation, migration, invasion, and in vivo growth, offering improved diagnostic and therapeutic outcomes compared to existing antibodies.
Implementation Method 1
an antibody which binds to a pancreatic adenocarcinoma upregulated factor (PAUF) protein
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to an antibody specifically binding to a pancreatic adenocarcinoma upregulated factor (PAUF) protein and use thereof. The antibody of the present invention binds to a PAUF protein with high specificity and affinity and thereby inhibits the proliferation, migration, invasion, and in vivo growth, and thus the antibody of the present invention can be effectively used in the field of diagnosis and treatment of diseases such as cancer in which PAUF proteins are overexpressed.